TABLE 2.
COVID-19 infection in non-immunocompromised patients by vaccination status
| Variable | Unconfirmed vaccine status, N = 1 343 841 | Primary series (VAX2)a, N = 338 252 | VAX3a, N = 81 181 |
|---|---|---|---|
| Sex | |||
| Male | 615 261 (46%) | 129 403 (38%) | 30 100 (37%) |
| Female | 728 580 (54%) | 208 849 (62%) | 51 081 (63%) |
| Age | |||
| 18–45 | 786 274 (59%) | 167 232 (49%) | 31 786 (39%) |
| 46–65 | 388 757 (29%) | 113 768 (34%) | 27 725 (34%) |
| >65 | 168 810 (13%) | 57 252 (17%) | 21 670 (27%) |
| Race/Ethnicity | |||
| White | 856 821 (64%) | 238 589 (71%) | 59 262 (73%) |
| Black/African American | 155 436 (12%) | 34 525 (10%) | 6729 (8.3%) |
| Hispanic/Latino | 140 423 (10%) | 36 360 (11%) | 7358 (9.1%) |
| Other/Unknown | 191 161 (14%) | 28 778 (8.5%) | 7832 (9.6%) |
| Comorbidities | |||
| CKD | 34 783 (2.6%) | 13 194 (3.9%) | 4342 (5.3%) |
| Hypertension | 222 952 (17%) | 80 662 (24%) | 23 685 (29%) |
| Diabetes | 120 566 (9.0%) | 43 859 (13%) | 12 708 (16%) |
| COPD/Asthma | 107 209 (8.0%) | 34 011 (10%) | 9539 (12%) |
| Cancer | 41 892 (3.1%) | 16 145 (4.8%) | 6238 (7.7%) |
| CAD | 44 909 (3.3%) | 16 575 (4.9%) | 5478 (6.7%) |
| CHF | 36 506 (2.7%) | 11 703 (3.5%) | 3544 (4.4%) |
| PVD | 32 610 (2.4%) | 12 930 (3.8%) | 4149 (5.1%) |
| Liver | 10 680 (0.8%) | 3539 (1.0%) | 923 (1.1%) |
| Obesity | |||
| BMI >30 | 243 837 (18%) | 62 050 (18%) | 15 653 (19%) |
| Missing | 801 923 (60%) | 206 491 (61%) | 43 608 (54%) |
| Time period | |||
| Pre-Delta (<June 20, 2021) | 392 000 (29%) | 6505 (1.9%) | 89 (0.1%) |
| Delta (June 20, 2021–December 19, 2021) | 495 743 (37%) | 137 794 (41%) | 6670 (8.2%) |
| Omicron (≥December 20, 2021) | 456 098 (34%) | 193 953 (57%) | 74 422 (92%) |
a
Infections occurred ≥14 days following COVID-19 vaccine.